FOR RESEARCH USE ONLY — All compounds sold for in vitro laboratory research  •  99%+ PURITY GUARANTEED  •  THIRD-PARTY HPLC & MASS SPECTROMETRY VERIFIED  •  COLD-CHAIN OPTIMISED SHIPPING  • 
Home / Compound Library / Thymosin Alpha-1
COA ↓
Product
COA Doc
SYN-2627
99.2% Purity SYN-2627 Research Grade HPLC Verified

Thymosin Alpha-1

28-Amino-Acid Thymic Immunomodulator · Research Grade

Select Strength — 5mg

$140.00
C₁₂₉H₂₁₅N₃₃O₅₅ MW: 3108.29 g/mol CAS: 62304-98-7
Out of Stock

Notify me when back in stock

For in vitro laboratory research use only. Not for human consumption, diagnostic, or therapeutic use.

Certificate of Analysis

BATCH VERIFICATION

Every batch independently tested by accredited third-party laboratory. Full COA available on request.

Current Batch
HPLC Purity
Lot Number SYN-2627-TA1
Test Date
Labeled 99.2%
Actual 99.2%
HPLC Purity
Lot Number SYN-2526-TA1
Test Date
Labeled 99.2%
Actual 99.5%

Research Data

KEY FINDINGS

🧬
35+
Countries with Regulatory Approval
Approved as Zadaxin (SciClone Pharma) in 35+ countries for HBV and cancer immunotherapy
🔬
−38%
Mortality Reduction (COVID-19)
Severe COVID-19 mortality reduction vs. standard care — Liu Y et al., 2020
✅
99.2%
HPLC-Verified Purity
Current batch SYN-2627, third-party accredited lab
❄️
36mo
Lyophilised Shelf Life
At −20°C sealed under inert atmosphere — extended stability

Mechanisms of Action

IN VITRO RESEARCH OVERVIEW

Data presented from peer-reviewed in vitro studies. All findings are laboratory observations only.

🔬 COVID-19 Clinical Data

38% Mortality Reduction in Severe COVID-19

Liu et al. conducted a retrospective analysis of 76 severe COVID-19 patients treated with TA-1 vs. standard care, documenting 38% mortality reduction — attributed to restoration of exhausted T-cell populations, reduction in cytokine storm severity, and TLR9-mediated immune activation.

Mortality (TA-1 + SOC) −38%
Mortality (SOC alone) 0%
🔬 38% severe COVID-19 mortality reduction — validating TA-1's role in rescuing T-cell exhaustion in acute viral immunosuppression.
PMID 32585691 — Clin. Infect. Dis.
38 %
COVID-19 Severe Disease Mortality Reduction

Thymosin Alpha-1 (Zadaxin) is approved in 35+ countries for hepatitis B and cancer immunotherapy. In severe COVID-19, it demonstrated 38% mortality reduction vs. standard care alone — acting via TLR9-mediated dendritic cell maturation, T-cell activation, and restoration of immune exhaustion markers.

Severe COVID-19 Mortality — TA-1 vs. Standard Care
Mortality (TA-1 + standard care) −38%
Mortality (standard care only) 0%
Source: Liu Y et al., Clin. Infect. Dis., 2020

Analytical Data

PURITY VERIFICATION

Purity by Method — Batch SYN-2627-TA1
Specification Value
CAS Number 62304-98-7
Molecular Formula C₁₂₉H₂₁₅N₃₃O₅₅
Molecular Weight 3108.29 g/mol
Purity (HPLC) 99.2%
Appearance White lyophilised powder
Solubility Soluble in water (1 mg/mL)
Storage −20°C long-term / 2–8°C short-term
Shelf Life 36 months from production date
Research Grade Yes — For In Vitro Use Only
📊

What Research Has Shown

TRIAL RESULTS

COVID-19 Mortality Trial — Clin. Infect. Dis., 2020

38 %

Severe COVID-19 Mortality Reduction vs. Standard Care Alone

TA-1 + Standard care −38%
Standard care only 0%

Comparative Activity Profile

Thymosin Alpha-1
🛡️

In Vitro Safety Data

SAFETY PROFILE

Thymosin Alpha-1 has one of the most comprehensive clinical safety records of any research peptide — approved as Zadaxin in 35+ countries with Phase II/III trial data across hepatitis B, hepatitis C, cancer immunotherapy, and sepsis. Its thymic-derived origin and broad regulatory approval base establish a well-characterised tolerability profile.

Observed Adverse Indicators

15%

Injection-site erythema/mild pain

low
8%

Transient fatigue

low
3%

Mild flu-like symptoms

low
0%

Serious adverse events (Zadaxin trials)

low

⚠️ Theoretical Concern

Regulatory Approval & Clinical Safety Context

TA-1 (Zadaxin) is one of the best-studied research peptides in terms of regulatory review — approved in over 35 countries with established Phase II/III safety datasets in immunocompromised patient populations.

  • Approved as Zadaxin in 35+ countries — most comprehensive regulatory safety database of any research peptide
  • Phase II/III HBV trials: minimal adverse events, no dose-limiting toxicity at therapeutic doses
  • Endogenous thymic peptide origin — derived from natural thymosin fraction 5, not a novel xenobiotic
  • For in vitro laboratory research use only — not for human or veterinary administration
❓

Researcher Reference

FREQUENTLY ASKED QUESTIONS

Peer-Reviewed Literature

RESEARCH CITATIONS

Clinical Infectious Diseases
Thymosin Alpha-1 in Severe COVID-19 — Reduced Mortality
2020 Liu Y et al.
PMID 32585691 — View on PubMed

All citations refer to published peer-reviewed in vitro research. Data presented for scientific reference only. No claims made regarding human therapeutic use.

$140.00
Spend $100.00 more for free shipping
$0 Free at $100
Top Compounds →